FAX NO. 6176070530 RECEIVED CENTRAL FAX CENTER

MAY 2 5 2004 FICIAL

PTO/SB/81/(09/03)

Approved for use through 11/30/2005. OMB 0651-0035

Section and Trial and Mr. Office LLS. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no pe	rsons are regulre	U.S. ed to respond to	Patent and Trac a collection of in	lemark Office; U formation unless	.S. DEI # dispis	PARTMENT OF COMMERCI IVS a valid OMB control numbe
		Application Number		09/976,219		
		Filing Date		10/12/2001		
POWER OF ATTORNE		First Named Inventor		Yat Sun Or		
and CORRESPONDENCE ADD				rin Analogs for the Treatment of ine Diseases		
INDICATION FORM		Art Unit		1653		
(MBISA/ISW CIIII		Examiner Name		Samuel W. Liu		
		Attorney Docket No.		ENP-030		
I hereby revoke all previous powers of attorney given in the above-identified patent application and hereby appoint:						
x Practitioners associated with the Customer Number 21874						
OR Practitioner(s) named below:						
Name	Registratio Number	n	Name			Registration Number
as my/our attomey(s) or agent(s) to pro States Patent and Trademark Office co			ntified above,	and to transac	t all b	usiness in the United
Please recognize or change the correspondence address for the above-identified application to: X						
City Boston State		MA	MA		Zip	02205
Country US	Telephi) 439-4444			(617) 439-4170
I am the: Applicant/Inventor. X Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record Name Enanta Pharmaceuticals, Inc. by Paul J. Mellett, Senior Vice President and CFO Signature Date Telephone 617-607-0800 NOTE: Signatures of all the inventors of assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
Total of 2 forms are submitted.						
I hereby certify that this correspondence is being facsimile transmitted to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Dated: 5/25/014						

PTC/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. STATEMENT UNDER 37 CFR 3.73(b) RECEIVED Applicant/Patent Owner: ENANTA PHARMACEUTICALS, INC. CENTRAL FAX CENTER Filed/Issue Date: October 12, 2001 Application No./Patent No.: 09/976,219 MAY 7 5 2004 Entitled: Cyclosporin Analogs for the Treatment of AutoImmune Diseases ENANTA PHARMACEUTICALS, INC. CORPORATION (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government 1. \(\subseteq\) the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is in the patent application/patent identified above by virtue of either. A. [/] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012256 , Frame 0613 , or for which a copy thereof is attached. OR B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown 1. From: -- Ta: • The document was recorded in the United States Patent and Trademark Office at , or for which a copy thereof is attached. , Frame To: The document was recorded in the United States Patent and Trademark Office at Reel Frame , or for which a copy thereof is attached. To: The document was recorded in the United States Patent and Trademark Office at ____, Frame _, or for which a copy thereof is attached. [] Additional documents in the chain of title are listed on a supplemental sheet. [] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Mellett Typed∕dr printed name 617-607-0800 **Gigr**lature Telephone number Senior Vice President and CFO Title

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection la estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DQ NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.